Clinical trial
An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-β2.
NCT00844064 is registered in ClinicalTrials.gov with Isarna Therapeutics GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-β2.
- Lead sponsor
- Isarna Therapeutics GmbH
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2005
- Completion date
- November 30, 2011
- Enrollment
- 62 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.